High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments

MeSH terms

• Adolescent
• Adult
• Aged
• Antibodies, Monoclonal / therapeutic use
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Combined Chemotherapy Protocols / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Bleomycin / administration & dosage
• Bleomycin / adverse effects
• Bone Marrow Purging
• Cisplatin / administration & dosage
• Cisplatin / adverse effects
• Combined Modality Therapy
• Cyclophosphamide / administration & dosage
• Cyclophosphamide / adverse effects
• Cytarabine / administration & dosage
• Cytarabine / adverse effects
• Dexamethasone / administration & dosage
• Dexamethasone / adverse effects
• Doxorubicin / administration & dosage
• Doxorubicin / adverse effects
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Forecasting
• Graft Survival
• Hematopoietic Stem Cell Transplantation*
• Humans
• Leucovorin / administration & dosage
• Leucovorin / adverse effects
• Lymphoma, Non-Hodgkin / drug therapy*
• Lymphoma, Non-Hodgkin / mortality
• Lymphoma, Non-Hodgkin / therapy
• Male
• Methotrexate / administration & dosage
• Methotrexate / adverse effects
• Middle Aged
• Prednisone / administration & dosage
• Prednisone / adverse effects
• Remission Induction
• Risk Factors
• Rituximab
• Survival Analysis
• Transplantation Conditioning / adverse effects
• Treatment Outcome
• Vincristine / administration & dosage
• Vincristine / adverse effects